
State Street SPDR S&P Pharmaceuticals ETF (XPH)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
57.61 - Open
58.35 - Bid 58.50 x 160000
- Ask 58.60 x 60000
- Day's Range
57.94 - 58.74 - 52 Week Range
38.95 - 59.46 - Volume
92,692 - Avg. Volume
70,409 - Net Assets 307.87M
- NAV 58.57
- PE Ratio (TTM) 19.38
- Yield 0.69%
- YTD Daily Total Return 4.55%
- Beta (5Y Monthly) 0.88
- Expense Ratio (net) 0.35%
Performance Overview: XPH
View MoreTrailing returns as of 5/1/2026. Category is Health.
People Also Watch
Holdings: XPH
View MoreTop 10 Holdings (20.91% of Total Assets)
Sector Weightings
Recent News: XPH
View MoreResearch Reports: XPH
View More-
Daily – Vickers Top Buyers & Sellers for 12/30/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
-
Verisign to Continue to Benefit as Operator of Some of the Internet’s Most Valuable Real Estate
Verisign is an operator of critical infrastructure within the domain name system, or DNS. As the registry for some of the world’s most popular TLDs, .com and .net, Verisign directs DNS resolvers to the appropriate registry where IP addresses are stored. Verisign’s control over its TLDs is regulated by ICANN and the NTIA and are subject to contract renewal every six years. The company generates revenue through annual subscriptions allowing customers to use .com and .net as their TLD of choice for their respective websites.
RatingPrice Target -
Vornado Realty Trust: Dropping Coverage
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
RatingPrice Target -
Kenvue: Takeover by Kimberly-Clark Gives Shareholders a Lifeline
Kenvue is the world’s largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.
RatingPrice Target










